Press & Publications

Acclaimed Musician Patrick Girondi and his Company San Rocco Therapeutics Featured in International Fair,...

Project Manager Megan Euker Recognition as Ambassador of the Project ‘Scienza Partecipata’ for the...

DRUG PROSPECTS DWINDLING, CASH RUNWAY NOW DRYING UP, ABANDONED BY MANAGEMENT, ALL WHILE ATTEMPTING TO RETAIN...

Patrick Girondi, CEO of San Rocco Therapeutics (SRT) met Wednesday, May 17, 2023 with Robert F. Kennedy Jr....

San Rocco Therapeutics filed an action for violations of federal RICO (Federal Racketeering and Corrupt...

A civil action has been filed, charging violations of the Federal Racketeering and Corrupt Organizations Act...

From May 12, 2023 to July 23rd, the distinguished institution will be the venue for two-time U.S./Italy...

After San Rocco Therapeutics (SRT) founder Patrick Girondi’s son was diagnosed with Thalassemia in 1992,...

The high prices are caused by corruption and out of control executive compensations. Even small start-up...

Insertional oncogenesis is an inherent risk of lentiviral vectors because they are able to integrate into...

SRT gene therapy vector, since 2012, two out of three patients treated with myelosuppression and the SRT...

Is the filing of a citizen petition with the U.S. Food and Drug Administration (FDA) an appropriate action...

San Rocco, whose potential rival gene therapy for thalassemia is in preclinical development, had wanted FDA...

Gene therapy-focused biotech venture bluebird bio announced recently that the U.S. Food and Drug...

LOS ANGELES, CA, UNITED STATES, July 15, 2022 /EINPresswire.com/ -- Megan Euker, acclaimed Project Manager,...

Settlement Broken In a short summary of these long years, TrialSite continues to chronicle Patrick Girondi...

TAMPA, Fla.--(BUSINESS WIRE)--Using the SRT vector and myelosuppressive preparation therapy, Memorial Sloan...

Through studies in mice and in humans, Stuart Orkin showed that GATA-1 is a master transcriptional regulator...

Patrick Girondi said he was inspired to found his San Rocco Therapeutics company to find a cure for his...

The globin genes are archetypal tissue-specific genes that are silent in most tissues but for late-stage...

After three decades of research, Memorial Sloan Kettering Cancer Center investigators may have found a new...

Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1...

The ongoing battle between Bluebird Bio and tiny Errant Gene Therapeutics has escalated into a fullblown...

In developing LentiGlobin, now listed as the second most expensive drug in the world at $1.8 million,...

Simmering feud between Bluebird and a rival continues with allegations of patent fraud Bluebird Bio was hit...

The conflicts between biotech venture Errant Gene Therapeutics LLC (“EGT”) and publicly traded Bluebird Bio...

Bluebird Is Sued Over Patents Related to Blood-Disease Drug By Christopher Yasiejko...

Wilmer Cutler Attorneys Defending Memorial SloanKettering in Patent Suit Over Blood Disorder Treatments...

Errant Gene Therapeutics Becomes San Rocco Therapeutics twenty-eight years after its establishment. Errant...

Lentiviral vector ALS20 yields high hemoglobin levels with low genomic integrations for treatment of...

UK’s NICE Rejects bluebird bio: Questions Value Price Tag & Nominal Clinical Evidence While...

Errant Gene Therapeutics, LLC (“EGT”) Pushing Clinical Trial of Potentially Curative Treatment for...

Last year, TrialSite published ​“A Familyman’s Battle Against the Forefront of the Capitalist Medicine: the...

Former Chicago trader battles medical science giants over gene therapy dealA trial promises a rare glimpse...

Ex-Trader Takes Sloan-Kettering to Court Over Gene Therapy DealPatrick Girondi claims cancer institute and...

GENE THERAPY WITH THE LENTIVIRAL VECTOR TNS9.3.55 PRODUCES LONG-TERM IMPROVEMENT IN SEVERE ß-THALASSEMIA...

Errant Gene Therapeutics’ Gene Therapy Vector Shows Promise for Sickle Cell Disease and Thalassemia Patients...

GENE THERAPY WITH THE LENTIVIRAL VECTOR TNS9.3.55 PRODUCES LONG-TERM IMPROVEMENT IN SEVERE ß-THALASSEMIA All...

CHICAGO--(BUSINESS WIRE)-- Errant Gene Therapeutics (“EGT”) announces, that on April 30, 2020, the New York...

Pharma Drama: bluebird bio, Inc. Directors Accused of “Grossly Excessive” Compensation While separate Errant...

New York Court Sanctions Bluebird Bio, Paving Way for EGT to Proceed with Lawsuit in Massachusetts for...

Cell and Gene Therapy for the Beta-Thalassemia: Advances and Prospects The beta-thalassemias are inherited...

This is an article about the father of a Thalassemia patient who fights for his son. From his days as a...

Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene...

Federal Grant Awarded To Chicago BioMed Firm To Advance Research on Thalassemia. Among the World's Largest...

β-globin could treat β-thalassaemia SCD. The stable introduction of a functional β-globin gene in...